ACT has awarded £4,700 to support Professor Hammond's research into novel strategies to improve treatment response in children with Diffuse Midline Glioma (DMG) — one of the most aggressive and difficult-to-treat childhood brain tumours.

Diffuse Midline Glioma (DMG) is the second most common high-grade brain tumour in children, carrying an extremely poor prognosis — with an average survival of no more than 12 months after diagnosis. While radiotherapy can slow the disease, it is not curative, and there is an urgent need for new treatments that can be combined with it to improve outcomes.

This six-week project, led by Dr Ester Hammond at the University of Oxford, aims to provide the scientific foundation for a new therapy combination that could be implemented quickly in a clinical setting — with the potential to directly benefit children with DMG.